| 1 | Heart age estimated using explainable advanced electrocardiography |
|--|---|
| 2 | Thomas Lindow, MD, PhD ^{1,2,3*} , Israel Palencia-Lamela, ^{1,4*} Todd T Schlegel, MD ^{5,6} , |
| 3 | Martin Ugander, MD, PhD ^{1,5} |
| 4 5 7 8 9 10 11 12 | Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia Department of Clinical Physiology, Research and Development, Växjö Central Hospital, Region Kronoberg, Sweden Clinical Physiology, Clinical Sciences, Lund University, Sweden Davidson College, Davidson, North Carolina, USA Department of Clinical Physiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden Nicollier-Schlegel SARL, Trélex, Switzerland |
| 13 | *Shared first-authorship by equal contribution |
| 14 | |
| 15 16 17 18 19 20 21 22 | Fundings: TL is currently under the support of postdoctoral research grants from The Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian Society of Clinical Physiology; Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of Sydney. |
| 23 24 25 26 27 28 | Author contributions: TL and IPL contributed to study design, performed the data analysis, wrote the first manuscript drafts, prepared the figures, and are shared first authors by equal contributions. TTS curated the data, contributed to study design, performed the prediction modeling, and critically revised the manuscript. MU designed the study, provided supervision, and critically revised the manuscript. All authors read and approved the final version of the manuscript. |
| 29 | Competing interests: |
| 30 | TL, IPL: None |
| 31 32 33 34 | TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation consultancy using software that can quantify the advanced ECG measures used in the current study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is developing commercial applications of advanced ECG technology used in the current study. |
| 35 | |
| 36 | Corresponding author: Martin Ugander, martin.ugander@ki.se, Professor of Cardiac |

- 37 Imaging, University of Sydney, Sydney, Australia, and Karolinska Institute, Sweden.
- 38

| 39 | Background: Electrocardiographic (ECG) Heart Age conveying cardiovascular risk has been |
|----|--|
| 40 | estimated by both Bayesian and artificial intelligence approaches. We hypothesized that |
| 41 | explainable measures from the 10-second 12-lead ECG could successfully predict Bayesian |
| 42 | ECG Heart Age. |
| 43 | Methods: Advanced analysis was performed on ECGs from healthy subjects and patients |
| 44 | with cardiovascular risk or proven heart disease. Regression models were used to predict a |
| 45 | Bayesian 5-minute ECG Heart Age from the standard resting 10-second 12-lead ECG. The |
| 46 | difference between 10-second ECG Heart Age and chronological age was compared. |
| 47 | Results : In total, 2,771 subjects were included (n=1682 healthy volunteers, n=305 with |
| 48 | cardiovascular risk factors, n=784 with cardiovascular disease). Overall, 10-second Heart Age |
| 49 | showed strong agreement with the 5-minute Heart Age (R ² =0.94, p<0.001, mean±SD bias |
| 50 | 0.0 ± 5.1 years). The difference between 10-second ECG Heart Age and chronological age was |
| 51 | 0.0 ± 5.7 years in healthy individuals, 7.4 ± 7.3 years in subjects with cardiovascular risk factors |
| 52 | (p<0.001), and 14.3 \pm 9.2 years for patients with cardiovascular disease (p<0.001). |
| 53 | Conclusions: ECG Heart Age can be accurately estimated from a 10-second 12-lead ECG in |
| 54 | a transparent and explainable fashion based on known ECG measures, without artificial |
| 55 | intelligence techniques. The difference between ECG Heart Age and chronological age |
| 56 | increases markedly with cardiovascular risk and disease. |
| 57 | Keywords: vascular age; electrocardiography cardiovascular risk prediction; advanced |
| 58 | electrocardiography; vectorcardiography |

59

61 Background

| 62 | Cardiovascular disease is a significant contributor to mortality, and pathological processes |
|----|--|
| 63 | begin early and can progress silently for many years ¹⁻³ . Many of the risk factors for |
| 64 | developing cardiovascular disease are lifestyle-related ⁴ . Fortunately, several of these are |
| 65 | modifiable, and risk can therefore be reduced for example by smoking cessation, dietary |
| 66 | changes and increased physical activity ^{5,6} . To accomplish this, an individual must fully |
| 67 | understand their risk and become motivated to act upon it. One way of communicating risks |
| 68 | to the patient is to present the risk as a "Heart Age", which can be contrasted to the patient's |
| 69 | chronological age. A Heart Age can either be determined by translating risk factor scores to |
| 70 | what age that score would represent in an individual with no risk factors, or it can be based on |
| 71 | electrocardiographic changes ⁷⁻¹² . Describing the risk to the patient using Heart Age has been |
| 72 | reported to reduce metabolic risk factors and may have the advantage of being easily |
| 73 | understood by the patient ^{11,13} . A similar approach has been applied when conveying risk to |
| 74 | smokers by describing how 'old' their lungs are, and such an approach increased the chance |
| 75 | of smoking cessation ¹⁴ . |
| | |

76 Moving beyond but not excluding basic ECG measurements such as heart rate and waveform 77 amplitudes and durations, the diagnostic output from the ECG can be further substantially 78 improved by using combinations of advanced ECG measures from 12-lead-ECG-derived vectorcardiography and waveform complexity¹⁵⁻¹⁷. An accurate ECG Heart Age using 79 80 advanced, 5-minute, 12-lead ECG was developed in 2014, based on Bayesian statistics⁹. The 81 Bayesian approach was transparent in so much as the advanced ECG measures contributing to 82 the ECG Heart Age were well-described. After being trained on a set of healthy individuals, 83 this approach yielded increased ECG Heart Ages for subjects at risk of cardiovascular disease and even higher ECG Heart Ages for those with established cardiovascular disease⁹. 84 85 However, the reliance on 5-minute, high-fidelity 12-lead ECG recordings lessens the

| 86 | likelihood of widespread clinical use. If standard 10-second ECG recordings could be used |
|----|---|
| 87 | instead, the clinical impact might be enhanced. Moreover, artificial intelligence has been used |
| 88 | to estimate ECG Heart Age using the 10-second resting 12-lead ECG ^{7,8,10} . However, artificial |
| 89 | intelligence techniques are limited by their "black box" approach, whereby the clinician does |
| 90 | not have transparency as to the exact source(s) of the changes in the ECG that can affect an |
| 91 | ECG Heart Age or other output ^{18,19} . Therefore, the aim of the study was to predict 5-minute |
| 92 | ECG Heart Age from measures available by 10-second 12-lead ECG, and to compare the 10- |
| 93 | second ECG Heart Age to chronological age in healthy subjects, subjects with cardiovascular |
| 94 | risk factors, and patients with established cardiovascular disease. We hypothesized that 10- |
| 95 | second 12-lead ECG recordings could accurately predict Bayesian ECG Heart Ages derived |
| 96 | from 5-minute 12-lead ECG recordings. |

97

98 Methods

A database of de-identified patients with both 5-minute and 10-second 12-lead ECG 99 recordings was utilized for the study⁹. Within that database, healthy individuals, patients at 100 101 cardiovascular risk, and patients with established cardiovascular disease were included. All 102 healthy subjects were low-risk asymptomatic volunteers with absence of any cardiovascular 103 or systemic disease, based on clinical history and physical examination. Exclusion criteria for 104 the healthy subjects included increased blood pressure at physical examination (≥140/90 mm 105 Hg), treatment for hypertension or diabetes, or active smoking. Patients with established 106 cardiovascular disease were included based on the presence of either coronary heart disease 107 (determined by coronary angiography with at least one obstructed vessel (\geq 50%) in at least one major native coronary vessel or coronary graft, or, if coronary angiography was either 108 109 unavailable or clinically not indicated, one or more reversible perfusion defects on 99m-Tctetrofosmin single-photon emission computed tomography $(SPECT)^{20-22}$), left ventricular 110

| 111 | hypertrophy (LVH) based on imaging evidence of at least moderate, concentric wall |
|-----|---|
| 112 | thickening according to guidelines of the American Society of Echocardiography ²³ , left |
| 113 | systolic dysfunction (left ventricular ejection fraction $\leq 50\%$) at echocardiography, cardiac |
| 114 | magnetic resonance imaging (CMR) or SPECT, or findings suggestive of |
| 115 | dilated/hypertrophic/ischemic cardiomyopathy at echocardiography or CMR ¹⁶ . Finally, |
| 116 | subjects at cardiovascular risk were included based on the presence of cardiovascular risk |
| 117 | factors such as hypertension or diabetes but no confirmed established cardiovascular disease ⁹ . |
| 118 | Based on the above, three groups of study participants were included: healthy subjects, |
| 119 | subjects at cardiovascular risk, and patients with established cardiovascular disease. By |
| 120 | methodological design, onlyhealthy subjects were initially included when considering optimal |
| 121 | measures of ECG available from 10-second 12-lead ECG for predicting the 5-minute ECG |
| 122 | Heart Age. The 10-second ECG measures considered for the prediction model included: (1) |
| 123 | From the conventional ECG: heart rate, R-to-R, P-wave, PR, QRS, QT, QTc, and TQ interval |
| 124 | durations, as well as the conventional ECG amplitudes and axes; (2) From the transformation |
| 125 | of the 12-lead ECG to the Frank X, Y and Z lead vectorcardiogram (VCG) via Kors' |
| 126 | transform ²⁴⁻²⁸ : the spatial means and peaks QRS-T angles, the spatial ventricular gradient and |
| 127 | its individual QRS and T components, the spatial QRS- and T-wave axes (azimuths and |
| 128 | elevations), waveform amplitudes and areas, including those in the three individual |
| 129 | vectorcardiographic planes, and spatial QRS-and T-wave velocities; and (3) measures of |
| 130 | QRS-and T-wave waveform complexity based on singular value decomposition after signal |
| 131 | averaging ²⁹⁻³¹ . |
| 132 | For all study participants, the difference between the 10-second ECG Heart Age and the |

133 chronological age was also calculated. Results were then compared between the three groups

134 defined above. All participants gave written informed consent. All recordings were obtained

135 under Institutional Review Board (IRB) approvals from NASA's Johnson Space Center and

136 partner hospitals that fall under IRB exemptions for previously collected and de-identified

137 data. The study was performed in accordance with the Declaration of Helsinki.

138 Statistical analysis

139 Continuous variables were described using mean and standard deviation (SD). The chi-140 squared test was used to test for proportional differences between groups. Student's t test was 141 used to compare group means. The 10-second ECG Heart Age was first derived only in the 142 healthy subject group through a process of feature selection, via optimized stepwise 143 procedures, of measures available from 10-s, standard-fidelity ECG recordings, first using 144 univariable linear regression, and finally as multivariable linear regression, to best predict the 5-minute ECG Heart Age⁹. The best model was defined as the model with highest R^2 value 145 146 that was also the most parsimonious, i.e., a model with statistically equal performance that 147 incorporated a lesser number of measures was considered more parsimonious due to less 148 proneness to over-fitting. The best model from the healthy volunteers was then applied 149 forward to an expanded population that also included the other two groups (cardiovascular 150 risk and cardiovascular disease, respectively), while not changing any of the included 151 variables, and only allowing optimization of the included coefficients. The final sex-specific 152 model was then applied across all three groups as the 10-secondECG Heart Age, and 153 comparisons with 5-minute ECG Heart Age are presented as scatter plots and Bland-Altman 154 plots. A two-sided p-value of 0.05 was used as to define statistical significance. Statistical 155 analyses were performed using SAS JMP version 11.0, SAS Institute Inc, Cary, NC, USA, 156 and R version 3.5.3R, R Foundation for Statistical Computing, Vienna, Austria, 157 https://www.R-project.org/.

158

160 **Results**

161 In total, 2,771 patients were included (n=1682 healthy volunteers, n=305 subjects with 162 cardiovascular risk factors, n=784 with cardiovascular disease). Baseline characteristics are 163 presented in Table 1. The ECG measures included in the final prediction models are presented 164 in Table 2 (males) and Table 3 (females). 165 The 10-second ECG Heart Age showed excellent agreement with the 5-minute Heart Age (R²=0.94, p<0.001, mean±SD bias 0.0±5.2 years), Figure 1. Agreement was strong for both 166 males and females ($R^2=0.91$, p<0.001, and $R^2=0.92$, p<0.001 respectively). In healthy 167 168 subjects, there was no difference in ECG Heart Age and chronological age $(0.0\pm5.7 \text{ years})$. In 169 subjects with cardiovascular risk factors, the difference was higher (7.4 ± 7.3 years, p<0.001). 170 Patients with cardiovascular disease showed the largest difference between ECG Heart Age

and chronological age (14.3±9.2 years, p<0.001 when compared to subjects at cardiovascular
risk), Figure 2.

173 Discussion

174 We found that ECG Heart Age based on measures of advanced ECG can be accurately

175 predicted from standard resting 10-second 12-lead ECG recordings. This facilitates

176 widespread use of ECG Heart Age in routine clinical settings, since neither specialized ECG

177 machines nor unusually lengthy recordings are necessary. Also, if digital ECG raw data are

available and the recording is of acceptable quality, ECG Heart Age can be retrospectively

determined. Further, we found ECG Heart Age to be similar to chronological age in healthy

180 individuals, while the ECG Heart Age was increasingly older with increasing cardiovascular

- 181 disease status. This suggests that the ECG Heart Age is likely to provide accurate
- 182 cardiovascular risk prediction, although validation in other datasets is necessary.

184 *Explainability and transparency of variables that contribute to ECG Heart Age*

185 For an estimation of Heart Age to be accurate in predicting an age that is similar to the 186 chronological age when the heart is healthy, and increased when the heart is diseased, it is 187 desirable that the included ECG measures change with age, and that the change is augmented 188 with increasing cardiovascular risk or disease severity. Beyond age itself, the two ECG 189 measures that had the strongest influence (highest t ratio) on the model were P-wave duration and spatial QT duration, and these measures fit this description well. P-wave duration 190 increases with age³², and increased P-wave duration can be seen in advanced cardiovascular 191 pathologies, e.g. heart failure and cardiac amyloidosis³³. Similarly, QT duration increases 192 with age³⁴. Further, QT prolongation is associated with increased of cardiovascular risk, even 193 beyond the rare long QT syndromes³⁵, and with incrementally increased risk in advanced 194 ages³⁶. These general characteristics are also true for increased heart rate and for leftward 195 shifting of the frontal plane QRS axis³⁷⁻⁴⁰. The other measures included in the score track 196 197 changes in the vectorcardiographic QRS and T, and in T-wave complexity by singular value 198 decomposition. Such changes are also known to occur in conditions associated with increased cardiovascular risk, such as hypertension and diabetes⁴¹, and in established cardiovascular 199 disease, in which they often provide strong diagnostic and prognostic information^{24-27,29-31}. 200 201 Notably, these changes are not easily detectable by visual interpretation of a standard 12-lead 202 ECG. How these ECG measures can affect the ECG Heart Age is exemplified in Figure 3. 203 Taken together, the described ECG measures that contribute in a multivariable fashion to the 204 ECG Heart Age all have physiologically reasonable associations with age and disease in a 205 way that is transparent to the assessing clinician, thus providing important explainability to the model. 206

207

209 Differences compared to Bayesian 5-minute ECG Heart Age

| 210 | The original, Bayesian 5-minute ECG Heart Age requires information from measures of beat- |
|-----|---|
| 211 | to-beat heart rate and QT variability, ⁹ and of the root-mean square voltage or other aspects of |
| 212 | high-frequency (high fidelity) components of the QRS complex ⁴²⁻⁴⁴ . However, 10-second- |
| 213 | duration recordings of standard fidelity do not allow for such measures, and therefore they |
| 214 | were not included in the 10-second ECG Heart Age. However, unlike the original Bayesian 5- |
| 215 | minute ECG Heart Age, the 10-second ECG Heart Age should be derivable from any standard |
| 216 | 12-lead ECG machine, as long as it is sufficiently equipped with software that can measure |
| 217 | the included measures and calculate the 10-second ECG Heart Age. The presented 10-second |
| 218 | ECG Heart Age might therefore be anticipated to contribute to more widespread clinical |
| 219 | penetration and use. |

220

221 Comparison with other Heart (or Vascular) Ages

222 Different means of expressing cardiovascular risk by translating it into a heart or vascular age have recently been published¹³. Attia, et al, showed that by using a deep neural network 223 224 (DNN) artificial intelligence (AI) technique, a patient's chronological age could be predicted, 225 and that if the difference between the predicted and actual age was small, prognosis was good 226 ⁸. When Heart Age by Attia et al's technique was older than the chronological age, the risk of 227 future death was increased⁷. This corresponds well to the findings in our study that ECG 228 Heart Age increased with increasing burden of cardiovascular risk. However, the prognostic 229 value of the ECG Heart Age presented in the current study requires additional validation. Furthermore, another AI method similar to that of Attia et al reported similarly encouraging 230 results¹⁰. However, although the results of such AI studies are promising, DNN-based AI 231 232 techniques are inherently problematic in several respects, especially in relation to their lack of transparency and explainability, i.e., the 'black box' of AI^{18,19}. Without the ability to know the 233

| 234 | exact features of the 12-lead ECG that are most important in a given DNN model's output, |
|-----|---|
| 235 | both interpretability and ethical accountability are compromised ⁴⁵ . Moreover, it is effectively |
| 236 | impossible for a clinician to identify, when critically evaluating the diagnostic output of a |
| 237 | DNN-based AI model, the possible contribution to the result from methodological artifact or |
| 238 | bias merely related to noise or to differing technical specifications between different ECG |
| 239 | machines ⁴⁶ . Alternatively, it is not possible to know if unanticipated results are possibly just |
| 240 | related to excess dependency on the particular characteristics of a given DNN AI model's |
| 241 | training set ⁴⁷ . In addition, a major flaw in both DNN-based AI models is that the age |
| 242 | predictions were made using datasets including individuals with both cardiovascular risk |
| 243 | factors and established disease ^{8,10} . For ECG Heart Age to be used as a marker of |
| 244 | cardiovascular risk, it is imperative that ECG Heart Age agrees with chronological age in |
| 245 | healthy populations, since it is the deviations from the line of identity in this relationship that |
| 246 | form the basis of the assumed risk increase ⁸ . |
| 247 | Hence, we believe that the pursuit of an ECG Heart Age developed from heart-healthy |
| 248 | subjects of varying ages, but without a black-box DNN or related AI methodology is valuable, |
| 249 | and that the present results provide sufficient confirmation of accuracy to encourage further |
| 250 | development. In addition, models in which the assessments were based on age predictions in |
| 251 | healthy subjects will likely outperform models that were not. And finally, the use of more |
| 252 | transparent regression models will also increase the ability of clinicians to better understand |
| 253 | the origin of any unexpected result, and to thereafter relay it to the patient with a more |
| 254 | convincing sense of trust and ethical accountability ⁴⁵ . |
| 255 | |
| 256 | Limitations |

Using the same dataset for training and validation, our results can only be considered asproof-of-concept. Although the difference between ECG Heart Age and the subjects'

| 259 | chronological | age increased | with inc | creasing c | ardiovascul | lar risk | and/or | disease, | the pro | ognostic |
|-----|---------------|---------------|----------|---------------------------------------|-------------|----------|--------|----------|---------|----------|
| | | | | · · · · · · · · · · · · · · · · · · · | | | | | | |

- 260 value is unknown. Also, although ECG Heart Age was highly accurate, the precision cannot
- 261 be reliably defined in this study. These aspects therefore need to be addressed in future
- studies.
- 263
- 264 Conclusion
- 265 We show that ECG Heart Age can be accurately, transparently, and explainably estimated
- from a standard 10-s, resting 12-lead ECG utilizing multiple, discrete conventional and
- 267 advanced ECG measures. The difference between ECG Heart Age and subjects'
- 268 chronological age increases with increasing cardiovascular risk and disease. The prognostic
- 269 value of our transparent and explainable 10-second ECG Heart Age requires prospective
- 270 evaluation in future studies.
- 271

273 **References**

| 274 | 1 | Bergström, G. et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the |
|-----|---|--|
| 275 | | General Population. Circulation 144, 916-929, doi:10.1161/circulationaha.121.055340 |
| 276 | | (2021). |
| 277 | 2 | Townsend, N. et al. Cardiovascular disease in Europe: epidemiological update 2016. |
| 278 | | Eur Heart J 37, 3232-3245, doi:10.1093/eurheartj/ehw334 (2016). |
| 279 | 3 | Badimon, L. & Vilahur, G. Thrombosis formation on atherosclerotic lesions and |
| 280 | | plaque rupture. J Int Med 276, 618-632, doi:10.1111/joim.12296 (2014). |
| 281 | 4 | Andersson, C. & Vasan, R. S. Epidemiology of cardiovascular disease in young |
| 282 | | individuals. Nat Rev Cardiol 15, 230-240, doi:10.1038/nrcardio.2017.154 (2018). |
| 283 | 5 | Elliot, C. A. & Hamlin, M. J. Combined diet and physical activity is better than diet or |
| 284 | | physical activity alone at improving health outcomes for patients in New Zealand's |
| 285 | | primary care intervention. BMC Publ Health 18, 230, doi:10.1186/s12889-018-5152-z |
| 286 | | (2018). |
| 287 | 6 | Lim, S. S. et al. A comparative risk assessment of burden of disease and injury |
| 288 | | attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a |
| 289 | | systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224- |
| 290 | | 2260, doi:10.1016/s0140-6736(12)61766-8 (2012). |
| 291 | 7 | Ladejobi, A. O. et al. The 12-lead electrocardiogram as a biomarker of biological age. |
| 292 | | Eur Heart J - Dig Health2, 379-389, doi:10.1093/ehjdh/ztab043 (2021). |
| 293 | 8 | Attia, Z. I. et al. Age and Sex Estimation Using Artificial Intelligence From Standard |
| 294 | | 12-Lead ECGs. Circ Arrhythm Electrophysiol 12, e007284, |
| 295 | | doi:10.1161/circep.119.007284 (2019). |

| 296 | 9 | Ball, R. L., Feiveson, A. H., Schlegel, T. T., Starc, V. & Dabney, A. R. Predicting |
|-----|----|--|
| 297 | | "heart age" using electrocardiography. J Pers Med 4, 65-78, doi:10.3390/jpm4010065 |
| 298 | | (2014). |
| 299 | 10 | Lima, E. M. et al. Deep neural network-estimated electrocardiographic age as a |
| 300 | | mortality predictor. Nature Commun 12, 5117, doi:10.1038/s41467-021-25351-7 |
| 301 | | (2021). |
| 302 | 11 | Lopez-Gonzalez, A. A. et al. Effectiveness of the Heart Age tool for improving |
| 303 | | modifiable cardiovascular risk factors in a Southern European population: a |
| 304 | | randomized trial. Eur J Prev Cardiol 22, 389-396, doi:10.1177/2047487313518479 |
| 305 | | (2015). |
| 306 | 12 | Soureti, A., Hurling, R., Murray, P., van Mechelen, W. & Cobain, M. Evaluation of a |
| 307 | | cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. |
| 308 | | Eur J Cardiovasc Prev Rehab 17, 519-523, doi:10.1097/HJR.0b013e328337ccd3 |
| 309 | | (2010). |
| 310 | 13 | Groenewegen, K. A. et al. Vascular age to determine cardiovascular disease risk: A |
| 311 | | systematic review of its concepts, definitions, and clinical applications. Eur J Prev |
| 312 | | Cardiol 23, 264-274, doi:10.1177/2047487314566999 (2016). |
| 313 | 14 | Parkes, G., Greenhalgh, T., Griffin, M. & Dent, R. Effect on smoking quit rate of |
| 314 | | telling patients their lung age: the Step2quit randomised controlled trial. BMJ 336, |
| 315 | | 598-600, doi:10.1136/bmj.39503.582396.25 (2008). |
| 316 | 15 | Maanja, M. et al. The electrical determinants of increased wall thickness and mass in |
| 317 | | left ventricular hypertrophy. J Electrocardiol 58, 80-86, |
| 318 | | doi:10.1016/j.jelectrocard.2019.09.024 (2020). |
| 319 | 16 | Schlegel, T. T. et al. Accuracy of advanced versus strictly conventional 12-lead ECG |
| 320 | | for detection and screening of coronary artery disease, left ventricular hypertrophy and |

- 321 left ventricular systolic dysfunction. *BMC Cardiovasc Disord* **10**, 28,
- 322 doi:10.1186/1471-2261-10-28 (2010).
- 323 17 Johnson, K. et al. Advanced Electrocardiography Identifies Left Ventricular Systolic
- 324 Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over Time. J

325 *Cardiovasc Dev Dis* **2**, 93-107, doi:10.3390/jcdd2020093 (2015).

- 326 18 Gladding, P. A., Hewitt, W. & Schlegel, T. T. Going deep with ecg and aortic
- 327 stenosis: Touchdown or incomplete pass? J Am Heart Assoc 9, e016193-e016193,

328 doi:10.1161/JAHA.120.016193 (2020).

- 329 19 The Lancet Respiratory Medicine, L. R. M. Opening the black box of machine
- 330 learning. *Lance Respir Med* **6**, 801-801, doi:10.1016/S2213-2600(18)30425-9 (2018).
- 331 20 Vrtovec, B., Sinkovec, M., Starc, V., Radovancevic, B. & Schlegel, T. T. Coronary
- artery disease alters ventricular repolarization dynamics in type 2 diabetes. *Pacing Clin Electrophysiol* 28 Suppl 1, S178-181, doi:10.1111/j.1540-8159.2005.00076.x
- 334 (2005).
- 33521Persson, E., Carlsson, M., Palmer, J., Pahlm, O. & Arheden, H. Evaluation of left
- 336 ventricular volumes and ejection fraction by automated gated myocardial SPECT
- 337 versus cardiovascular magnetic resonance. *Clin Physiol Funct Imaging***25**, 135-141,
- 338 doi:10.1111/j.1475-097X.2005.00599.x (2005).
- 33922Trägårdh, E. *et al.* High-frequency electrocardiogram analysis in the ability to predict
- 340 reversible perfusion defects during adenosine myocardial perfusion imaging. *J*

```
341 Electrocardiol40, 510-514, doi:10.1016/j.jelectrocard.2007.03.242 (2007).
```

- 34223Lang, R. M. *et al.* Recommendations for cardiac chamber quantification by
- 343 echocardiography in adults: an update from the American Society of
- 344 Echocardiography and the European Association of Cardiovascular Imaging. *Eur*
- 345 *Heart J Cardiovasc maging***16**, 233-270, doi:10.1093/ehjci/jev014 (2015).

- 346 24 Yamazaki, T., Froelicher, V. F., Myers, J., Chun, S. & Wang, P. Spatial QRS-T angle
- 347 predicts cardiac death in a clinical population. *Heart rhythm* **2**, 73-78,
- 348 doi:10.1016/j.hrthm.2004.10.040 (2005).
- 349 25 Fayn, J., Rubel, P., Pahlm, O. & Wagner, G. S. Improvement of the detection of
- 350 myocardial ischemia thanks to information technologies. *Int J Cardiol* **120**, 172-180,
- 351 doi:10.1016/j.ijcard.2006.09.025 (2006).
- 352 26 Kardys, I. *et al.* Spatial QRS-T angle predicts cardiac death in a general population.
- 353 *European heart journal***24**, 1357-1364, doi:10.1016/S0195-668X(03)00203-3 (2003).
- 354 27 Horinaka, S. *et al.* Ventricular gradient variability. New ECG method for detection of
- ischemic heart disease. J Electrocardiol 28, 177-183, doi:10.1016/S0022-
- 356 0736(05)80255-9 (1995).
- 35728Kors, J. A., van Herpen, G., Sittig, A. C. & van Bemmel, J. H. Reconstruction of the
- 358 Frank vectorcardiogram from standard electrocardiographic leads: diagnostic

359 comparison of different methods. *Eur Heart J* **11**, 1083-1092 (1990).

Zabel, M. *et al.* Analysis of T-wave morphology from the 12-lead electrocardiogram
for prediction of long-term prognosis in male US veterans. *Circulation* 105, 1066-

362 1070, doi:10.1161/hc0902.104598 (2002).

- 363 30 Okin, P. M. et al. Repolarization Abnormality for Prediction of All-Cause and
- 364 Cardiovascular Mortality in American Indians: The Strong Heart Study. *J Cardiovasc*

365 *Electrophysiol* **16**, 945-951, doi:10.1111/j.1540-8167.2005.40808.x (2005).

- 366 31 Priori, S. G. *et al.* Evaluation of the spatial aspects of T-wave complexity in the long-
- 367 QT syndrome. *Circulation* **96**, 3006-3012, doi:10.1161/01.CIR.96.9.3006 (1997).
- 368 32 Chhabra, L., Devadoss, R., Chaubey, V. K. & Spodick, D. H. Interatrial Block in the
 369 Modern Era. *Curr Cardiol Rev*10, 181-189,
- 370 doi:10.2174/1573403X10666140514101748 (2014).

- 371 33 Lindow, T. & Lindqvist, P. The Prevalence of Advanced Interatrial Block and Its
- 372 Relationship to Left Atrial Function in Patients with Transthyretin Cardiac

373 Amyloidosis. *J Clin Med* **10**, doi:10.3390/jcm10132764 (2021).

- 374 34 Rautaharju, P. M., Mason, J. W. & Akiyama, T. New age- and sex-specific criteria for
- 375 QT prolongation based on rate correction formulas that minimize bias at the upper
- 376 normal limits. *Int J Cardiol* **174**, 535-540, doi:10.1016/j.ijcard.2014.04.133 (2014).
- 377 35 Shah, S. R., Park, K. & Alweis, R. Long QT Syndrome: A Comprehensive Review of
- 378 the Literature and Current Evidence. *Curr Prob Cardiol* **44**, 92-106,
- doi:10.1016/j.cpcardiol.2018.04.002 (2019).
- 380 36 Nielsen, J. B. *et al.* Risk prediction of cardiovascular death based on the QTc interval:
- 381 evaluating age and gender differences in a large primary care population. *Eur Heart J*

382 **35**, 1335-1344, doi:10.1093/eurheartj/ehu081 (2014).

- 383 37 Goorakani, Y. et al. Correlation of resting heart rate with anthropometric factors and
- 384 serum biomarkers in a population-based study: Fasa PERSIAN cohort study. *BMC*

385 *Cardiovas Disord* **20**, 319-319, doi:10.1186/s12872-020-01594-y (2020).

386 38 Ogliari, G. *et al.* Resting heart rate, heart rate variability and functional decline in old

387 age. *Can Med Assoc J* **187**, E442-e449, doi:10.1503/cmaj.150462 (2015).

- 388 39 Morcet, J. F., Safar, M., Thomas, F., Guize, L. & Benetos, A. Associations between
- heart rate and other risk factors in a large French population. J Hyperten s17, 1671-
- 390 1676, doi:10.1097/00004872-199917120-00003 (1999).
- 40 Evans, J. G., Prior, I. A. & Tunbridge, W. M. Age-associated change in QRS axis:
- 392 intrinsic or extrinsic ageing? *Gerontology***28**, 132-137, doi:10.1159/000212523
- 393 (1982).

- 394 41 Bergfeldt, L. *et al.* Spatial peak and mean QRS-T angles: A comparison of similar but
- different emerging risk factors for cardiac death. *J Electrocardiol***61**, 112-120,
- 396 doi:10.1016/j.jelectrocard.2020.05.013 (2020).
- 397 42 Ringborn, M. M. D. et al. Comparison of high-frequency QRS components and ST-
- 398 segment elevation to detect and quantify acute myocardial ischemia. *J Electrocardiol*
- **43**, 113-120, doi:10.1016/j.jelectrocard.2009.11.009 (2010).
- 400 43 Trägårdh, E., Pahlm, O., Wagner, G. S. & Pettersson, J. Reduced high-frequency QRS
- 401 components in patients with ischemic heart disease compared to normal subjects. J
- 402 *Electrocardiol* **37**, 157-162, doi:10.1016/j.jelectrocard.2004.02.004 (2004).
- 403 44 Schlegel, T. T. *et al.* Real-Time 12-Lead High-Frequency QRS Electrocardiography
- 404 for Enhanced Detection of Myocardial Ischemia and Coronary Artery Disease. *Mayo*405 *Clin Proc* **79**, 339-350, doi:10.4065/79.3.339 (2004).
- 406 45 Yoon, C. H., Torrance, R. & Scheinerman, N. Machine learning in medicine: should

407 the pursuit of enhanced interpretability be abandoned? *J Med Ethics*,

- 408 doi:10.1136/medethics-2020-107102 (2021).
- 409 46 Brisk, R. *et al.* The effect of confounding data features on a deep learning algorithm to
- 410 predict complete coronary occlusion in a retrospective observational setting. *Eur*
- 411 *Heart J Dig Health* **2**, 127-134, doi:10.1093/ehjdh/ztab002 (2021).
- 412 47 Siontis, K. C. et al. Use of Artificial Intelligence Tools Across Different Clinical
- 413 Settings: A Cautionary Tale. *Circ Cardiovasc Qual Outcomes***14**, e008153,
- 414 doi:10.1161/circoutcomes.121.008153 (2021).
- 415
- 416

| | All (n=2,771) | Healthy (n=1,682) | Subjects at CV risk (n=305) | Patients with CV disease (n=784) | р |
|----------------------------------|------------------|----------------------|-----------------------------------|--|---------|
| Age, years | 46.2 (16.0) | 38.6 13.0) | 54.8 (11.2) | 59.0 (13.2) | < 0.001 |
| Male sex, n (%) | 1645 (59.4) | 999 (59.4) | 163 (53.4) | 483 (61.6) | 0.048 |
| 5-minute ECG Heart Age, years | 51.1 (21.7) | 38.3 14.1) | 61.9 (13.2) | 74.2 (15.6) | < 0.001 |
| CAD, n (%) | 421 (15.2) | - | - | 421 (53.7) | - |
| ICM, n (%) | 120 (4.3) | - | - | 120 (15.3) | - |
| HCM, n (%) | 92 (3.3) | - | - | 92 (11.7) | - |
| LVH, n (%) | 96 (3.5) | - | - | 96 (12.2) | - |
| NICM, n (%) | 53 (1.9) | - | - | 53 (6.8) | - |

Table 1. Baseline characteristics

Age and 5-minute ECG Heart Age are presented as mean (standard deviation). Abbreviations: CAD: coronary artery disease; ICM: ischemic cardiomyopathy; HCM: hypertrophic cardiomyopathy; LVH: left ventricular hypertrophy; NICM: non-ischemic cardiomyopathy

418

| Measure | Estimate | Standard error | t ratio |
|---|----------|-------------------|---------|
| (Intercept) | -60.575 | 2.353 | -25.73 |
| Age, years | 0.820 | 0.007 | 113.73 |
| P-wave duration, ms | 0.288 | 0.007 | 39.99 |
| Spatial QT interval, ms | 0.081 | 0.004 | 22.86 |
| Heart rate, min ⁻¹ | 0.242 | 0.012 | 20.02 |
| QRS max amplitude in VCG lead Y, μV | -0.007 | 0.000 | -18.20 |
| Frontal plane QRS axis, radians | -5.834 | 0.395 | -14.75 |
| T-wave complexity, $Ln \sum (EV3:8) / (EV1-EV2)$, unitless | 2.152 | 0.164 | 13.12 |
| Spatial ventricular gradient minus Spatial mean QRS, mV*s | -55.841 | 4.464 | -12.51 |
| Male sex (value=1) | 1.996 | 0.215 | 9.27 |
| QRS RMS in VCG vector magnitude lead, mV | 10.315 | 1.612 | 6.40 |
| QRS average spatial velocity in VCG vector magnitude lead, mV/s | 0.106 | 0.017 | 6.30 |
| Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, % | 0.033 | 0.009 | 3.55 |

Table 2. Measures included in the 10-second ECG Heart Age (male patients)

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

| Measure | Estimate | Standard error | t ratio | |
|---|----------|-------------------|---------|--|
| (Intercept) | -70.477 | 2.662 | -26.47 | |
| Age, years | 0.850 | 0.008 | 104.26 | |
| P-wave duration, ms | 0.331 | 0.008 | 40.73 | |
| Spatial QT interval, ms | 0.095 | 0.004 | 23.58 | |
| Heart rate, min ⁻¹ | 0.281 | 0.014 | 20.57 | |
| QRS max amplitude in VCG lead Y, µV | -0.009 | 0.000 | -18.54 | |
| Frontal plane QRS axis, radians | -6.354 | 0.447 | -14.21 | |
| Spatial ventricular gradient minus Spatial mean QRS, mV*s | -67.642 | 5.049 | -13.40 | |
| T-wave complexity, $Ln \sum (EV3:8) / (EV1-EV2)$, unitless | 2.359 | 0.185 | 12.72 | |
| QRS RMS in VCG vector magnitude lead,mV | 11.701 | 1.822 | 6.42 | |
| QRS average spatial velocity in VCG vector magnitude lead, mV/s | 0.116 | 0.019 | 6.10 | |
| Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, % | 0.034 | 0.010 | 3.22 | |
| Abbraviatione: In: Natural logarithm: EV: Figanvalues: VCC: vactocardiographic: PMC: root mean equare | | | | |

| Table 3. Measures | s included in the | e 10-second EC | G Heart Age | (female natients) |
|-------------------|-------------------|----------------|-------------|--------------------|
| | mendada mi mi | | O Hourt Hge | (ionuio putionito) |

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

| 439 | Figure 1. Left panel: Scatter plot showing the relation between the 10-second ECG Heart Age |
|-----|--|
| 440 | and the 5-minute ECG Heart Age in all participants. The R ² value was 0.94 (p<0.001). Right |
| 441 | panel: Bland-Altman plot showing the difference between the 10-second and 5-minute ECG |
| 442 | Heart Age in relation to the mean of both ECG Heart Ages. The agreement between methods |
| 443 | is strong, with minimal deviation from the identity line (dashed) or bias (0.0 ± 5.2 years). |
| 444 | |
| 445 | Figure 2. |
| 446 | Panel A: The difference between the 10-second ECG Heart Age and chronological age in |
| 447 | healthy subjects (left, dark green), subjects at cardiovascular (CV) risk (middle, light blue), |
| 448 | and patients with CV disease (right, yellow). On average, there is no difference between ECG |
| 449 | Heart Age and chronological age in healthy subjects. ECG Heart Age is higher in subjects at |
| 450 | CV risk, and highest for those with overt CV disease. |
| 451 | Panel B: Scatter plots showing the relationship between the 10-second ECG Heart Age and |
| 452 | chronological age in healthy subjects (left, dark green), subjects at CV risk (middle, light |
| 453 | blue), and patients with CV disease (right, yellow). The dashed diagonal line is the identity |
| 454 | line, i.e. indicating no difference between ECG Heart Age and chronological age. |
| 455 | |
| 456 | Figure 3. Example of the transparency and explainability of the ECG Heart Age from two |
| 457 | subjects with equal chronological age but different ECG Heart Ages, illustrated by a |
| 458 | commensurately aged female heart, but a disproportionately aged male heart. The ECG |
| 459 | measures for each of the two patients are shown in the table in the middle of the figure, |
| 460 | presented in the order of the relative strength (strongest first, based on t ratio [not shown]) of |
| 461 | contribution to the ECG Heart Age. Notably, P-wave duration is markedly different between |
| 462 | these two patients, and heart rate is higher for the male than the female, helping drive the |
| 463 | ECG Heart Age higher in the male. The R-wave amplitude in lead Y is also much larger in the |

- 464 female, and the difference between the spatial ventricular gradient and the spatial mean QRS
- in the female is also larger, likely due to preserved T-wave amplitudes, contributing to her
- 466 relatively younger ECG Heart Age. Furthermore, likely due to ischemic myocardial injuries,
- 467 T-wave complexity is increased in the male, suggesting that increased myocardial
- 468 repolarization heterogeneity also contributes to driving ECG Heart Age higher in the male, in
- 469 spite of his shorter QT interval.









60-year old, healthy female without cardiovascular risk factors or medications 60-year old male with heart failure following myocardial infarction

ECG measures

| P-wave duration | 90 ms | 148 ms | |
|---|--------------|--------------|--|
| Spatial QT interval | 447 ms | 380 ms | |
| Heart rate | 55/min | 70/min | |
| QRS max amplitude in VCG lead Y | 835 μV | 299 µV | |
| Frontal plane QRS axis | 0.58 radians | 0.64 radians | |
| Spatial ventricular gradient - spatial mean QRS | 0.038 mV*s | 0.003 mV*s | |
| T-wave complexity, Ln | -1.92 | 1.21 | |
| QRS RMS in VCG vector magnitude lead | 0.43 mV | 0.31 mV | |
| QRS average spatial velocity in | 30.1 m\//s | 23.5 mV/s | |
| vector magnitude lead | 39.1111/5 | | |
| Portion of QRS loop in posterior superior | 10 7% | 25.2% | |
| quadrant of left sagital plane by VCG | 12.7 /0 | | |
| | | | |

